Open AccessPositron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Author(s) -
Daniel Persky,
Hongli Liu,
Deborah M. Stephens,
Sophie Park,
Nancy L. Bartlett,
Lode J. Swinnen,
Paul M. Barr,
Jerome D. Winegarden,
Louis S. Constine,
Thomas J. Fitzgerald,
John P. Leonard,
Brad S. Kahl,
Michael LeBlanc,
Joo Y. Song,
Richard I. Fisher,
Lisa M. Rimsza,
Sonali M. Smith,
Thomas P. Miller,
Jonathan W. Friedberg
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.00999
Subject(s) - medicine , rituximab , vincristine , diffuse large b cell lymphoma , prednisone , positron emission tomography , lymphoma , aggressive lymphoma , oncology , nuclear medicine , cyclophosphamide , chemotherapy
Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)-directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.